Aastrom raises $5 million for commercialisation:
This article was originally published in Clinica
Executive Summary
Aastrom Bioscienceshas raised $5 million in a private placement to a single investor, in order to begin the commercialisation of its AastromReplicell cell production system and commence of trials in the US. The funding will allow the Ann Arbor, Michigan-based company to begin production-stage manufacture of the stem cell replication system which will be used to increase blood and immune system function for cancer and blood disease patients.
Register for our free email digests: